cur,1 2 and although routine screening of blood donors for syphilis has been called into question,3 it is still a legal requirement. Furthermore, there is an increasing tendency to use blood products which have been held at 22°C, at which temperature Treponema pallidum can survive for longer periods than at the normal refrigeration temperature of 4°C. There is thus a continuing need for an effective, practicable, and economical serological test.
The cardiolipin slide test for lipodial antibody has been relied on for many years, and in some centres has been adapted for use on automated blood grouping machines. In this centre the manual method has been preferred because of its greater sensitivity. Reactive sera are diluted 1 in 5 in control cell suspension and left to absorb for one hour at room temperature. They are spun and the supernatants titrated with test and control cells. Those that are still reactive at 1 in 10 are referred to Oxford Public Health Laboratory for confirmation.
Results
Over three months the "spin" modification and the formerly used "settle" method were performed in parallel on 21 807 donor and antenatal sera. There were 16 confirmed positive reactions, all detected by both methods. Sixty six samples had to be repeated by both methods, a further 98 by the "spin" method, and 107 by the "settle" method. Comparison of the titres of the 16 positive sera showed that the "spin" method usually yielded titres of one doubling dilution less than the "settle" method. This was also the case with the kit positive control. "Spin" and "settle" methods were also compared using sera from Panel 405 of the Division of Microbiological Reagents and Quality Control. The results agreed with the above trend (table 3) .
Discussion
The case for discarding cardiolipin tests and relying on TPHA for syphilis screening of blood donors has been made by Barbara et al, 7 and by the fact that in four years this centre has not found a single cardiolipin positive, TPHA negative case of syphilis. The time taken to perform the "settle" modification of TPHA, however, remained a problem that prevented us from relying on it exclusively. This has been solved by the introduction of the "spin" TPHA which compares very well with the established "settle' method and is rapid, sensitive, specific, cheap (0.98p per test) and well suited to mass screening. The slight reduction in sensitivity is compensated for by screening at 1/10 rather than 1/16 as used in the "settle" method. (Standard TPHA is usually used at 1/80, but for screening blood donors it is better to be over sensitive.)
Costs can be further reduced in two ways. Nuttall showed that reconstituted Fujirebio cells can be frozen in aliquots and thawed for use,8 which means that the larger 500 test kits supplied by Diamed Diagnostics can now be used. This reduces the price per test to 075p. A large part of the cost is in the extra buffer which must be bought for use with the compupet. A Microlab-M dilutor (VA Howe and Co Ltd, London), could make direct dilutions using no extra buffer and thus theoretically further reduce the price to 035p per test.
As well as the documented cost effectiveness in ante natal serology9 the screen for syphilis remains an important part of transfusion microbiology. Not only is it a legal requirement, but there is also the chance that a positive result could act as a surrogate marker for other infectious agents. Surrogate testing has been suggested for the human immunodeficiency virus (HIV)`0 and the agent of non-A, non-B hepatitis11; and the possibility should be considered that by excluding a TPHA positive donor, a centre might also be excluding a carrier of non-A, non-B hepatitis, or even someone who has acquired HIV, but in whom antibody is not detectable.
